adenine has been researched along with Headache in 3 studies
Headache: The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (33.33) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Sax, PE | 1 |
Wohl, D | 1 |
Yin, MT | 1 |
Post, F | 1 |
DeJesus, E | 1 |
Saag, M | 1 |
Pozniak, A | 1 |
Thompson, M | 1 |
Podzamczer, D | 1 |
Molina, JM | 1 |
Oka, S | 1 |
Koenig, E | 1 |
Trottier, B | 1 |
Andrade-Villanueva, J | 1 |
Crofoot, G | 1 |
Custodio, JM | 1 |
Plummer, A | 1 |
Zhong, L | 1 |
Cao, H | 1 |
Martin, H | 1 |
Callebaut, C | 1 |
Cheng, AK | 1 |
Fordyce, MW | 1 |
McCallister, S | 1 |
Takeo, C | 1 |
Negishi, E | 1 |
Nakajima, A | 1 |
Ueno, K | 1 |
Tatsuno, I | 1 |
Saito, Y | 1 |
Amano, K | 1 |
Hirai, A | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Trea[NCT01780506] | Phase 3 | 872 participants (Actual) | Interventional | 2012-12-26 | Completed | ||
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treat[NCT01797445] | Phase 3 | 872 participants (Actual) | Interventional | 2013-03-12 | Completed | ||
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Genvoya) as Maintenance Treatment of HIV-1/Hepatitis B Virus (HBV)-Coinfected Patients: an Observational Study[NCT03425994] | 275 participants (Actual) | Observational [Patient Registry] | 2018-02-06 | Active, not recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
(NCT01780506)
Timeframe: Baseline; Week 144
Intervention | cells/µL (Mean) |
---|---|
E/C/F/TAF | 323 |
E/C/F/TDF | 310 |
(NCT01780506)
Timeframe: Baseline; Week 48
Intervention | cells/µL (Mean) |
---|---|
E/C/F/TAF | 235 |
E/C/F/TDF | 221 |
(NCT01780506)
Timeframe: Baseline; Week 96
Intervention | cells/µL (Mean) |
---|---|
E/C/F/TAF | 285 |
E/C/F/TDF | 271 |
(NCT01780506)
Timeframe: Baseline; Week 144
Intervention | mg/dL (Mean) |
---|---|
E/C/F/TAF | 0.04 |
E/C/F/TDF | 0.08 |
(NCT01780506)
Timeframe: Baseline; Week 48
Intervention | mg/dL (Mean) |
---|---|
E/C/F/TAF | 0.08 |
E/C/F/TDF | 0.11 |
(NCT01780506)
Timeframe: Baseline; Week 96
Intervention | mg/dL (Mean) |
---|---|
E/C/F/TAF | 0.05 |
E/C/F/TDF | 0.07 |
Hip BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 144
Intervention | percent change (Mean) |
---|---|
E/C/F/TAF | -0.826 |
E/C/F/TDF | -3.475 |
Hip BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 96
Intervention | percent change (Mean) |
---|---|
E/C/F/TAF | -0.951 |
E/C/F/TDF | -3.515 |
Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. (NCT01780506)
Timeframe: Baseline; Week 48
Intervention | percent change (Mean) |
---|---|
E/C/F/TAF | -0.865 |
E/C/F/TDF | -3.200 |
Spine BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 144
Intervention | percent change (Mean) |
---|---|
E/C/F/TAF | -0.809 |
E/C/F/TDF | -3.023 |
Spine BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 48
Intervention | percent change (Mean) |
---|---|
E/C/F/TAF | -1.337 |
E/C/F/TDF | -2.956 |
Spine BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 96
Intervention | percent change (Mean) |
---|---|
E/C/F/TAF | -0.907 |
E/C/F/TDF | -3.053 |
Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 144
Intervention | percent change (Median) |
---|---|
E/C/F/TAF | -24.6 |
E/C/F/TDF | 60.4 |
Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 48
Intervention | percent change (Median) |
---|---|
E/C/F/TAF | -32.8 |
E/C/F/TDF | 18.0 |
Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 96
Intervention | percent change (Median) |
---|---|
E/C/F/TAF | -33.5 |
E/C/F/TDF | 32.5 |
Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 144
Intervention | percent change (Median) |
---|---|
E/C/F/TAF | 37.4 |
E/C/F/TDF | 106.9 |
Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 96
Intervention | percent change (Median) |
---|---|
E/C/F/TAF | 11.3 |
E/C/F/TDF | 75.0 |
Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 48
Intervention | percent change (Median) |
---|---|
E/C/F/TAF | 6.9 |
E/C/F/TDF | 51.2 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01780506)
Timeframe: Week 48
Intervention | percentage of participants (Number) |
---|---|
E/C/F/TAF | 93.1 |
E/C/F/TDF | 92.8 |
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant. (NCT01780506)
Timeframe: Up to 144 weeks
Intervention | percentage of participants (Number) | ||
---|---|---|---|
Grade 1 | Grade 2 | Grade 3 | |
E/C/F/TAF | 31.3 | 6.0 | 0.2 |
E/C/F/TDF | 37.1 | 7.0 | 0.2 |
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant. (NCT01780506)
Timeframe: Up to 48 weeks
Intervention | percentage of participants (Number) | ||
---|---|---|---|
Grade 1 | Grade 2 | Grade 3 | |
E/C/F/TAF | 25.8 | 4.6 | 0 |
E/C/F/TDF | 32.3 | 4.9 | 0.2 |
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant. (NCT01780506)
Timeframe: Up to 96 weeks
Intervention | percentage of participants (Number) | ||
---|---|---|---|
Grade 1 | Grade 2 | Grade 3 | |
E/C/F/TAF | 28.8 | 5.1 | 0.2 |
E/C/F/TDF | 33.9 | 5.8 | 0.2 |
The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Weeks 48, 96, and 144 were analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01780506)
Timeframe: Weeks 48, 96. and 144
Intervention | percentage of participants (Number) | ||
---|---|---|---|
Week 48 | Week 96 | Week 144 | |
E/C/F/TAF | 86.4 | 84.4 | 84.6 |
E/C/F/TDF | 87.3 | 83.6 | 80.1 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Weeks 96 and 144 were analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01780506)
Timeframe: Weeks 96 and 144
Intervention | percentage of participants (Number) | |
---|---|---|
Week 96 | Week 144 | |
E/C/F/TAF | 89.2 | 86.9 |
E/C/F/TDF | 88.2 | 83.1 |
(NCT01797445)
Timeframe: Baseline; Week 48
Intervention | cells/µL (Mean) |
---|---|
E/C/F/TAF | 225 |
E/C/F/TDF | 200 |
(NCT01797445)
Timeframe: Baseline; Week 96
Intervention | cells/µL (Mean) |
---|---|
E/C/F/TAF | 274 |
E/C/F/TDF | 260 |
(NCT01797445)
Timeframe: Baseline; Week 48
Intervention | mg/dL (Mean) |
---|---|
E/C/F/TAF | 0.08 |
E/C/F/TDF | 0.12 |
(NCT01797445)
Timeframe: Baseline; Week 96
Intervention | mg/dL (Mean) |
---|---|
E/C/F/TAF | 0.04 |
E/C/F/TDF | 0.07 |
Hip BMD was assessed by DXA scan. (NCT01797445)
Timeframe: Baseline; Week 96
Intervention | percent change (Mean) |
---|---|
E/C/F/TAF | -0.364 |
E/C/F/TDF | -3.023 |
Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. (NCT01797445)
Timeframe: Baseline; Week 48
Intervention | percent change (Mean) |
---|---|
E/C/F/TAF | -0.420 |
E/C/F/TDF | -2.603 |
Spine BMD was assessed by DXA scan. (NCT01797445)
Timeframe: Baseline; Week 48
Intervention | percent change (Mean) |
---|---|
E/C/F/TAF | -1.278 |
E/C/F/TDF | -2.759 |
Spine BMD was assessed by DXA scan. (NCT01797445)
Timeframe: Baseline; Week 96
Intervention | percent change (Mean) |
---|---|
E/C/F/TAF | -1.017 |
E/C/F/TDF | -2.516 |
Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 48
Intervention | percent change (Median) |
---|---|
E/C/F/TAF | -29.3 |
E/C/F/TDF | 32.3 |
Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 96
Intervention | percent change (Median) |
---|---|
E/C/F/TAF | -31.0 |
E/C/F/TDF | 35.2 |
Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 96
Intervention | percent change (Median) |
---|---|
E/C/F/TAF | 16.9 |
E/C/F/TDF | 73.7 |
Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 48
Intervention | percent change (Median) |
---|---|
E/C/F/TAF | 13.3 |
E/C/F/TDF | 51.7 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01797445)
Timeframe: Week 48
Intervention | percentage of participants (Number) |
---|---|
E/C/F/TAF | 91.6 |
E/C/F/TDF | 88.5 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01797445)
Timeframe: Week 96
Intervention | percentage of participants (Number) |
---|---|
E/C/F/TAF | 84.0 |
E/C/F/TDF | 82.3 |
The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Weeks 48 and 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01797445)
Timeframe: Weeks 48 and 96
Intervention | percentage of participants (Number) | |
---|---|---|
Week 48 | Week 96 | |
E/C/F/TAF | 82.4 | 78.7 |
E/C/F/TDF | 80.7 | 76.8 |
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant. (NCT01797445)
Timeframe: Baseline to Week 48
Intervention | percentage of participants (Number) | ||
---|---|---|---|
Grade 1 | Grade 2 | Grade 3 | |
E/C/F/TAF | 27.3 | 4.7 | 0 |
E/C/F/TDF | 31.6 | 4.6 | 0 |
Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant. (NCT01797445)
Timeframe: Baseline to Week 96
Intervention | percentage of participants (Number) | ||
---|---|---|---|
Grade 1 | Grade 2 | Grade 3 | |
E/C/F/TAF | 31.8 | 5.4 | 0 |
E/C/F/TDF | 36.9 | 5.1 | 0 |
1 trial available for adenine and Headache
2 other studies available for adenine and Headache
Article | Year |
---|---|
Association of cytosine-adenine repeat polymorphism of the estrogen receptor-beta gene with menopausal symptoms.
Topics: Adenine; Cytosine; Depression; Dinucleotide Repeats; Estrogen Receptor beta; Female; Headache; Hot F | 2005 |
Three new drugs for HIV infection.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Did | 1998 |